News

Prostate-cancer researchers at the Duke Cancer Institute (DCI) have published a new study that may solve one of the mysteries of advanced metastatic prostate cancer: why do Black men experience a greater survival benefit from a personalized immunotherapy called sipuleucel-T immunotherapy than white men, when both groups have cancer that is resistant to hormonal therapy? Until now, the reasons baffled clinicians and researchers at the Duke Cancer Institute center for Prostate and Urologic Cancers (DPUC).

Michael Lipkin, MD, MBA, recently appeared on Endourology Sound Bites, a podcast series featuring experts in the field. He discussed various aspects of ureteroscopy that may affect outcome and complication rates.

Duke Pediatric Urology again was named #19 in the 2024 U.S. News and World Report Best Children’s Hospitals for Urology rankings.

Focal therapy of urologic cancers has been a strong interest of Duke Urology faculty for the past 15 years.

Patients gain access to genitourinary oncology specialists at three Wake County locations.

Former chief of the Division of Urology at Duke, David Paulson, MD, died on August 9, 2024. Dr. Paulson served as chief of the division from 1980 to 2003. 

DUHS Perioperative Services is pleased to announce the appointment of Michael Lipkin, MD, MBA, as the new Chief of Ambulatory Surgery DUHS, effective July 1, 2024.

The third edition of Imaging and Focal Therapy of Early Prostate Cancer, edited by Duke Urology’s Thomas Polascik, MD, FACS — along with Jean de la Rosette, MD, Rafael Sanchez-Salas, MD, and Ardeshir R. Rastinehad, DO —  will be published this fall.

Following a thorough external review of the department and its leadership, Gary Faerber, MD, has been named chair of the Department of Urology in the School of Medicine, starting July 1, 2024.

Judd W. Moul, M.D., FACS, James H. Semans, M.D., Distinguished Professor of Urologic Surgery in the School of Medicine, has been named to Newsweek’s first annual America's Best Prostate Cancer Surgeons 2024 list.